Coadministration of paracetamol (500 mg single dose) and rilpivirine had no effect on paracetamol AUC or Cmax. There was no change in rilpivirine AUC and Cmax, but Cmin increased by 26%. No dose adjustment is required. (This interaction study has been performed with a dose higher than the recommended dose for rilpivirine hydrochloride assessing the maximal effect on the co-administered medicinal product. The dosing recommendation is applicable to the recommended dose of rilpivirine of 25 mg once daily.)
Odefsey Summary of Product Characteristics, Gilead Sciences Ltd, January 2019.

Based on drug interaction studies conducted with the fixed dose combination or components of Odefsey, no clinically significant drug interactions have been either observed or expected when Odefsey is combined with acetaminophen. Coadministration of acetaminophen (500 mg single dose) and rilpivirine (150 mg once daily) was studied in 16 subjects. Rilpivirine Cmax. AUC and Cmin increased by 9%, 16% and 26%, respectively. Acetaminophen Cmax and AUC decreased by 3% and 8%. (This interaction study has been performed with a dose higher than the recommended dose for rilpivirine. The dosing recommendation is applicable to the recommended dose of rilpivirine 25 mg once daily.)
Odefsey US Prescribing Information, Gilead Sciences Inc, October 2018.